Patient characteristics
| Characteristic* . | No. of patients (%) . |
|---|---|
| Donor/recipient sex combination | |
| Female/Female | 23 (13) |
| Female/Male | 28 (15) |
| Male/Female | 64 (35) |
| Male/Male | 66 (36) |
| Patient diagnosis at transplantation | |
| Acute myeloid leukemia | 44 (24) |
| Acute lymphoblastic leukemia | 25 (14) |
| Chronic myelogenous leukemia | 27 (15) |
| Non-Hodgkin lymphoma | 38 (21) |
| Hodgkin disease | 4 (2) |
| Myelodysplastic syndrome | 21 (12) |
| Myelofibrosis | 6 (3) |
| Multiple myeloma | 14 (8) |
| Others | 2 (1) |
| Advanced disease† | 139 (77) |
| Conditioning regimen | |
| TBI-containing regimen | 114 (63) |
| Non-TBI-containing regimen | 67 (37) |
| GVHD prophylaxis | |
| MTX/CSP‡ | 161 (89) |
| Other regimens | 20 (11) |
| Patient/donor CMV serostatus1-153 | |
| Positive/Positive | 50 (28) |
| Positive/Negative | 40 (22) |
| Negative/Positive | 36 (20) |
| Negative/Negative | 54 (30) |
| Characteristic* . | No. of patients (%) . |
|---|---|
| Donor/recipient sex combination | |
| Female/Female | 23 (13) |
| Female/Male | 28 (15) |
| Male/Female | 64 (35) |
| Male/Male | 66 (36) |
| Patient diagnosis at transplantation | |
| Acute myeloid leukemia | 44 (24) |
| Acute lymphoblastic leukemia | 25 (14) |
| Chronic myelogenous leukemia | 27 (15) |
| Non-Hodgkin lymphoma | 38 (21) |
| Hodgkin disease | 4 (2) |
| Myelodysplastic syndrome | 21 (12) |
| Myelofibrosis | 6 (3) |
| Multiple myeloma | 14 (8) |
| Others | 2 (1) |
| Advanced disease† | 139 (77) |
| Conditioning regimen | |
| TBI-containing regimen | 114 (63) |
| Non-TBI-containing regimen | 67 (37) |
| GVHD prophylaxis | |
| MTX/CSP‡ | 161 (89) |
| Other regimens | 20 (11) |
| Patient/donor CMV serostatus1-153 | |
| Positive/Positive | 50 (28) |
| Positive/Negative | 40 (22) |
| Negative/Positive | 36 (20) |
| Negative/Negative | 54 (30) |
TBI indicates total body irradiation; GVHD, graft-versus-host disease; MTX/CSP, methotrexate/cyclosporine; and CMV, cytomegalovirus.
Median age (range) was 43.3 years (15.7-66.4 years).
Advanced disease: chronic myelogenous leukemia in accelerated phase and blast crisis, acute leukemias beyond first complete remission, refractory anemia with excess of blasts, multiple myeloma, Hodgkin and non-Hodgkin lymphomas beyond second complete remission or refractory, and myelofibrosis. Less advanced disease: chronic myelogenous leukemia in chronic phase, non-Hodgkin lymphomas in first/second complete remission and untreated first relapse, acute leukemia in first complete remission, refractory anemia.
MTX/CSP consisted of a short course of methotrexate and cyclosporine as previously described.21
In one case, donor serostatus is unknown for positive recipient.